… ProQR In-licenses Worldwide Rights to Ophthalmology Drug … said Daniel A. de Boer, chief executive officer of ProQR. “By acquiring the rights to QR-1123, we have … will be made in equity and others in cash or equity at ProQR’s discretion, and royalties on net sales of 20% through …
… ProQR to Present Axiomer RNA Editing Platform Technology at … & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Platenburg, co-founder and Chief Innovation Officer of ProQR. “With this approach disease-causing mutations can be …
ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5Rx, jetzt QR-1123, für autosomal-dominante Retinitis pigmentosa (adRP), eine seltene vererbte Form der Blindheit ohne zugelassene Therapie
… ProQR to Present at 3rd Annual Evercore ISI Virtual … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘ Events ’. The archived webcast will …
… ProQR Announces Successful Defense of a Key Axiomer® Patent … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3234134 B1 , which is related to …
… ProQR Announces Additional Sepofarsen Illuminate Trial … top-line announcement in February 2022 that Illuminate , ProQR’s pivotal Phase 2/3 trial of sepofarsen in CEP290 … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR Therapeutics to Host Virtual Analyst and Investor Event … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Program and member of the Scientific Advisory Board at ProQR. Prof. Gideon Hirschfield, MA(Oxon) MB BChir (Cantab) …
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023
Additi
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas